The FDA has been backlogged in drug factory inspections since before the COVID-19 pandemic, a new report found.

An AP analysis of Food and Drug Administration data shows that agency staffers have not returned to roughly 2,000 pharmaceutical manufacturing firms to conduct surveillance inspections since before the pandemic,

US regulators are struggling to catch up on drug factory inspections that were halted for COVID-19, AP finds.

An Associated Press investigation finds the Food and Drug Administration is struggling to inspect pharmaceutical manufacturing firms, which are overdue for required examinations.